Carboxyamidotriazole Orotate is under clinical development by Tactical Therapeutics and currently in Phase II for Glioblastoma Multiforme (GBM). According to GlobalData, Phase II drugs for Glioblastoma Multiforme (GBM) have a 23% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Carboxyamidotriazole Orotate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Carboxyamidotriazole Orotate overview
Carboxyamidotriazole orotate (CTO) is under development for the treatment of non-small cell lung cancer, head and neck cancer, metastatic colorectal cancer, glioblastoma multiforme, malignant glioma, prostate cancer and metastatic melanoma. It is administered orally. The drug candidate targets calcium-channel-mediated calcium influx. It was also under development for the treatment of age-related macular degeneration
It was under development for ovarian cancer, metastatic colorectal cancer, synovial sarcoma, renal Cell Carcinoma, synovial Sarcoma, leiomyosarcoma, squamous Non-Small Cell Lung Carcinoma, colon Carcinoma.
Tactical Therapeutics overview
Tactical Therapeutics operates in pharmaceutical and healthcare industry. It is headquartered in United States.
For a complete picture of Carboxyamidotriazole Orotate’s drug-specific PTSR and LoA scores, buy the report here.